299 related articles for article (PubMed ID: 21971004)
1. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection.
Naoi M; Maruyama W; Inaba-Hasegawa K; Akao Y
Int Rev Neurobiol; 2011; 100():85-106. PubMed ID: 21971004
[TBL] [Abstract][Full Text] [Related]
2. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
Naoi M; Maruyama W; Inaba-Hasegawa K
Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
[TBL] [Abstract][Full Text] [Related]
3. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
4. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
5. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Naoi M; Maruyama W
Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
[TBL] [Abstract][Full Text] [Related]
6. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
7. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.
Sanz E; Quintana A; Battaglia V; Toninello A; Hidalgo J; Ambrosio S; Valoti M; Marco JL; Tipton KF; Unzeta M
J Neurochem; 2008 Jun; 105(6):2404-17. PubMed ID: 18331475
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Tabakman R; Lecht S; Lazarovici P
Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders.
Naoi M; Maruyama W
Curr Pharm Des; 2010; 16(25):2799-817. PubMed ID: 20698822
[TBL] [Abstract][Full Text] [Related]
13. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection.
Naoi M; Maruyama W; Akao Y; Yi H; Yamaoka Y
J Neural Transm Suppl; 2006; (71):67-77. PubMed ID: 17447417
[TBL] [Abstract][Full Text] [Related]
14. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
[TBL] [Abstract][Full Text] [Related]
15. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
17. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
18. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Naoi M; Maruyama W; Inaba-Hasegawa K
Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
[TBL] [Abstract][Full Text] [Related]
19. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
Herraiz T; Arán VJ; Guillén H
Free Radic Res; 2009 Oct; 43(10):975-84. PubMed ID: 19669997
[TBL] [Abstract][Full Text] [Related]
20. Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2018 Nov; 125(11):1635-1650. PubMed ID: 29279995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
